BIOLOGIC RESPONSE MODIFIERS IN THE MANAGEMENT OF SUPERFICIAL BLADDER-CANCER

For the treatment of existing transitional-cell carcinoma or for proph ylaxis of recurrent disease, intravesical therapy should be chosen acc ording to stage. Papillary disease (stages Ta, T1) may be treated effe ctively either with an alkylating agent or with bacillus Calmette-Guer in (BCG). BCG is the agent of choice for the treatment of Hat carcinom a in situ (Tis), with the recommended treatment course comprising 12 w eekly and 12 monthly instillations. Intravesical interferon and many o f the other biologic response modifiers mentioned herein may be effect ive for patients with Ta disease who have failed BCG therapy.